Verismo Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Verismo Therapeutics, Inc. - overview
Established
2020
Location
Philadelphia, PA, US
Primary Industry
Biotechnology
About
Based in Pennsylvania, US, and founded in 2020, Verismo Therapeutics, Inc. provides treatment of solid tumors by pioneering CAR T-cell therapy. The company was co-founded by its CEO Bryan Kim. In February 2023, the firm raised USD 7 million in pre-series A funding led by investor BRV Capital Management.
The round was part of larger USD 33 million equity funding. The company offers chimeric antigen receptors (CARs) that improves T-cell-based cellular immunotherapy such as non-hematologic malignancies with few effective therapeutic options for the treatment of cancer. The firm provides KIR-CAR platform technology based SynKIR™ a CAR T cell therapy used for treatment of solid tumors using nature-inspired multichain receptor. The company plan to use the February 2023 funding to support the advancement of its studies and clinical trials.
Current Investors
BRV Capital Management, Institute for Follicular Lymphoma Innovation
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.verismotherapeutics.com
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.